| Lucitanib studied in …STUDIED_INderived12 of 12show fewer |
|---|
| → studied in | NCT07824505Phase 2 · completed Lucitanib (AL3810) in Patients With Advanced Thymic Carcinoma After Chemotherapy · 12 trials list this drug (0 active) | — | — | Thymus Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01283945Phase 1/Phase 2 · completed Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors · 12 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02053636Phase 2 · completed A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer · 12 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03992131Phase 1/Phase 2 · terminated A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) · 12 trials list this drug (0 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm,Urothelial Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04151563Phase 1/Phase 2 · withdrawn A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy · 12 trials list this drug (0 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04042116Phase 1/Phase 2 · suspended A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor · 12 trials list this drug (0 active) | — | — | Solid Neoplasm,Malignant Female Reproductive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02202746Phase 2 · terminated A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer · 12 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04254471Phase 2/Phase 3 · unknown This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients · 12 trials list this drug (0 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109016Phase 2 · terminated A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations · 12 trials list this drug (0 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02747797Phase 2 · withdrawn Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations · 12 trials list this drug (0 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03260179Phase 1 · unknown Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 · 12 trials list this drug (0 active) | — | — | Solid Neoplasm,Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03117101Phase 1 · completed Study of the AL3810 in the Treatment of Advanced Solid Tumor · 12 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |